Danish company Novo Nordisk AS in buyout agreement with Biopart

Through its current controlling shareholder company Biopart Ltda, Novo Nordisk AS is to acquire control of the Brazilian pharmaceutical company Biobrás, which specialises in insulin production. Denmark’s Novo Nordisk is acting through its subsidiary NN Holding do Brasil Ltda. The agreement was executed on December 12.

Get unlimited access to all Latin Lawyer content